Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Long-acting anticholinergic, specific antagonist of muscarinic receptors, which inhibits the bronchoconstrictive effects of acetylcholine.
Indicated in the treatment of asthma.
Inhaled administration.
Since the last update we have not found any published data on its excretion in breast milk.
Because of a very large volume of distribution along with a very low plasma concentration reached after inhalation (AEMPS 2019, Boehringer 2017), it must be very unlikely the passage of significant amounts into breastmilk.
Its almost nil oral bioavailability (AEMPS 2019, Boehringer 2017) would hamper the pass to the infant’s plasma through the breastmilk ingested.
Experts and scientific societies consider the use of inhaled anticholinergics during breastfeeding as low risk to the infant ((Hale, Lactmed, Amir 2011, National Asthma Education 2004).